Form 10-Q SYNERGY PHARMACEUTICALS, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Synergy Pharma (SGYP) Misses Q1 EPS Views; Offers Corp. Update
May 10, 2016 4:36 PM EDTSynergy Pharma (NASDAQ: SGYP) reported Q1 EPS of ($0.51), $0.28 worse than the analyst estimate of ($0.23).
2016 is off to a strong and promising start for Synergy, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of our first new drug application (NDA) for plecanatide in chronic idiopathic constipation (CIC), said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals. We continued to expand the utility and value of our uroguanylin-based platform technology while significantly strengthening our overall financial position. Moving forward, we believe we are well positioned to successfully execute on key... More
